

PDF issue: 2025-12-05

Detailed clinical course of fatal acute encephalopathy in children

Tomioka, Kazumi ; Nishiyama, Masahiro ; Nagase, Hiroaki ; Ishida, Yusuke ; Tanaka, Tsukasa ; Tokumoto, Shoichi ; Yamaguchi, Hiroshi ;…

(Citation)

Brain and Development, 41(8):691-698

(Issue Date) 2019-09

(Resource Type)
journal article

(Version)

Accepted Manuscript

(Rights)

© 2019 Published by Elsevier B.V. on behalf of The Japanese Society of Child Neurology.

This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/

(URL)

https://hdl.handle.net/20.500.14094/90007559



Detailed clinical course of fatal acute encephalopathy in children 1

2

- Kazumi TOMIOKA^{a*}, Masahiro NISHIYAMA^a, Hiroaki NAGASE^a, Yusuke ISHIDA^a, 3
- Tsukasa TANAKA^a, Shoichi TOKUMOTO^b, Hiroshi YAMAGUCHI^b, Daisaku 4
- TOYOSHIMA^b, Azusa MARUYAMA^b, Kyoko FUJITA^c, Kazunori AOKI^d, Yusuke 5
- SEINO^d, Kandai NOZU^a, Noriyuki NISHIMURA^a, Hiroshi KUROSAWA^d, Kazumoto 6
- IIJIMA^a 7

8

- ^a Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, 9
- 10 Japan
- ^b Department of Neurology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan 11
- ^c Department of Emergency and General Medicine, Hyogo Prefectural Kobe Children's 12
- 13 Hospital, Kobe, Japan
- 14 ^d Department of Pediatric Critical Care Medicine, Hyogo Prefectural Kobe Children's
- 15 Hospital, Kobe, Japan

16

17 32 text pages, 2 figures, 3 tables

- 2 *Corresponding author:
- 3 Kazumi TOMIOKA, M.D.
- Department of Pediatrics, Kobe University Graduate School of Medicine 4
- 7-5-2, Kusunoki-Cho, Chuo-Ku, Kobe, Hyogo 650-0017, Japan 5
- 6 Tel: +81-78-382-6090, Fax: +81-78-382-6099
- 7 E-mail: toimoka@med.kobe-u.ac.jp

Abstract

- 2 Objective: Although the mortality among previously healthy children with acute
- 3 encephalopathy (AE) is approximately 5%, their detailed clinical course has not been
- 4 clarified. The objective of the present study was to describe the detailed clinical course,
- in minutes, of fatal AE. 5
- 6 Methods: We retrospectively reviewed the medical records of five patients (from 6
- 7 months to 14 years of age) who previously had no neurological disorders and were
- 8 diagnosed with brain death due to AE between 2002 and 2018 at Kobe Children's
- 9 Hospital.
- 10 Results: The initial clinical symptoms were convulsion in three cases and impaired
- 11 consciousness in two. The earliest noted brain imaging abnormality was 7.5 h after
- neurological symptom detection. Liver enzymes and creatinine levels increased at 12
- initial examination, and sodium elevated gradually. All patients met the criteria of 13
- 14 systemic inflammatory response syndrome, disseminated intravascular coagulation,
- 15 and shock within 14 h of symptom detection. High dose steroids and targeted
- 16 temperature management were initiated 3.5-14 h after onset. Despite these therapies,

- 1 patients were diagnosed with brain death from 16 h to 4 days after initial neurological
- 2 symptoms. AE diagnoses were made between 4 h 29 min and 4 days after initial
- 3 neurological symptoms and included hemorrhagic shock and encephalopathy
- syndromes, Reye-like syndrome, and acute necrotizing encephalopathy in two, two, 4
- 5 and one patient(s), respectively.
- 6 Conclusions: We revealed the time series' of clinical events (e.g. SIRS, shock, DIC,
- 7 AE diagnosis, brain death, and treatments) and laboratory findings relative to initial
- 8 neurological symptom in fatal AE.

10 Keywords: acute encephalopathy, brain death, pediatrics

1. Introduction

1

2 Acute encephalopathy (AE) is a generic term for acute brain dysfunction, 3 caused by a viral infection in many cases [1]. Its main symptoms are acute onset 4 impaired consciousness and signs of increased intracranial pressure, often accompanied by convulsions or seizures [1, 2]. The mortality associated with AE is 5.6% and many 5 6 survivors have motor and intellectual disabilities or epilepsy [1, 2]. Severe cases of the 7 disease run a fulminant course, with rapid development of coma and signs of systemic 8 inflammatory response syndrome (SIRS), shock, multiple organ failure (MOF), and 9 disseminated intravascular coagulation (DIC) [1, 2]. A nationwide survey of pediatric 10 AE revealed that 11 patients died with hemorrhagic shock and encephalopathy 11 syndrome (HSES), and 11 patients died with acute necrotizing encephalopathy (ANE) 12 between 2007 and 2010 [2]. Detailed neuroimaging of 22 patients, including 8 fatal 13 cases, was presented in the largest case series for HSES yet published [3]. The outcomes 14 for and treatment of 34 patients, including 10 fatal cases, were reported in the largest 15 case series of ANE to date [4]. However, these studies did not focus on 16 minute-by-minute clinical time courses [2, 3, 4]. In a previous retrospective study, we

1 analyzed clinical and laboratory risk factors for mortality among children with seizure 2 and/or impaired consciousness accompanied by fever, and reported that aspartate 3 aminotransferase (AST) was associated with mortality [5]. However, the time courses of 4 fatal AE in this patient group were unknown. Given this background, the purpose of the present study was to describe the clinical course of fatal acute encephalopathy with a 5 6 temporal resolution of minutes. Specifically, we focus on the time series' of clinical 7 events (e.g. SIRS, shock, DIC, brain death, and treatments) and laboratory findings

9

10

12

13

14

15

16

8

2. Subjects and methods

relative to initial neurological symptom.

11 2.1. Patients

Kobe Children's Hospital (KCH) provides tertiary pediatric services to the Hyogo prefecture (population: 5.6 million), and approximately 100 children are admitted to KCH's pediatric intensive care unit (PICU) annually owing to neurological symptoms with fever. We used our database consisted of consecutive patients who were admitted to KCH with impaired consciousness and/or seizure with fever. Patients'

- 1 diagnoses in our database included, for example, complex febrile seizures (FS) or AE.
- 2 We extracted the patients who previously had no history of neurologic disease
- 3 (Pediatric Cerebral Performance Category [6], PCPC=1) and were ultimately
- 4 diagnosed with brain death (PCPC=6) because of AE from our database between
- October 2002 and March 2018, and reviewed their medical records. 5

7

16

2.2. Variables

8 We retrospectively reviewed the patients' clinical courses, including the 9 timing of their initial presentation, clinical criteria, examination, and treatment. 10 Clinical criteria included SIRS, DIC, shock, and a diagnosis of AE. Examinations 11 included laboratory assessments conducted 24 h after symptom onset, microbiological 12 cultures of blood and cerebrospinal fluid (CSF), rapid assays for influenza virus (Flu), 13 RS virus (RSV), rotavirus and real-time polymerase chain reaction for human herpes 14 virus types 6 and 7 (HHV-6 and -7), computed tomography (CT) imaging, magnetic 15 resonance imaging (MRI), and electroencephalography (EEG). EEGs taken in patients

with acute encephalopathy feature diffuse high amplitude slow waves or rhythmic

1 waves [7]. Thus, we recorded diffuse slow waves and electrical seizure activity, as was 2 proposed by Young, et al [8]. Patients were treated via intubation, administration of 3 anti-epileptic inotropic and/or dose steroids drugs, agents high (HDS; 4 methylprednisolone 30mg/kg), targeted temperature management (TTM; 36.0 ± 0.5 °C for at least 48 h using a cooling blanket), barbiturate coma therapy (BCT; bolus 5

injections of 1–2 mg/kg of thiamylal until we confirmed the burst-suppression pattern

on EEG, maintenance dosage 1–5mg/kg/h), and continuous hemodiafiltration (CHDF).

8

9

6

7

2.3. Clinical definitions

10 We defined onset time as that when initial neurological symptoms, including 11 convulsions or impaired consciousness, were first recognized in accordance with 12 criteria determined in previous studies [5, 9, 10]. We also defined brain death as including the following three factors: coma with EEG amplitude <10 µV, lack of 13 14 brainstem reflexes, and apnea. The criteria outlined in the International Consensus 15 Conference on Pediatric Sepsis and Organ Dysfunction were used to determine SIRS 16 and shock [11]. Briefly, shock is defined as sustained hypotension after sufficient

1 adequate infusion (≤-2SD below normal blood pressure determined based on patient 2 age). The criteria outlined by the Japanese Association for Acute Medicine were also used for the determination of DIC [12]. We used two criteria for the diagnosis of AE: 3 4 impaired consciousness for more than 24 h, or abnormal brain imaging [13]. HSES, Reve-like syndrome, and ANE were diagnosed in accordance with previous reports 5 6 [14-16]. 7 8 2.4. Ethical approval 9 The present study was approved by the local ethical committee of Kobe University 10 Graduate School of Medicine and KCH, which waived the need for informed consent 11 given that this was a retrospective observational study. 12 13 3. Results 14 3.1. Patients characteristics (Table 1) 15 The medical records of two boys and three girls, ranging in age from 6

months to 14 years, were examined in the present study. Symptoms prior to onset

1 included fever, cough, diarrhea, and vomiting for one or two days in four of the five 2 cases. The median patient body temperature on admission was 39.6 °C (38.1-41.0 °C). 3 Initial neurological symptoms included convulsions in three patients and impaired 4 consciousness in two. The duration of convulsion at onset was from 3 to 15 minutes 5 (unknown in case 5). Seizures were controlled with diazepam, and/or midazolam in 6 case 3, 4, and 5. Phenobarbital and thiamylal were administered to terminate clinical 7 and electrical seizures in case 1 and 2. Cases 3, 4 and 5 tested positive for Flu A and B, 8 respectively. All other virus examinations were negative. Blood and CSF cultures for 9 bacteria were also negative in all patients. Abnormalities on brain imaging included 10 edema, bleeding, and necrosis. Final diagnoses included HSES, Reve-like syndrome,

12

13

14

15

16

11

3.2. Time course of clinical events relative to onset (Table 2, Figure 1)

and ANE in two, two, and one patient(s), respectively.

Four patients (cases 1 - 4) were hospitalized 1 h after initial neurological symptom onset, and one patient (case 5) was hospitalized 11 h after onset. Two patients (cases 1 and 4) were admitted directly to our hospital. Patients 2 and 5 were

1 transferred 13 h after initial symptom onset, while patient 3 was transferred after only 2 4 h. Initial head CTs performed within approximately 3 h of symptom onset revealed 3 no abnormalities in three patients (cases 1, 3, and 4). In case 2, an initial head CT was 4 performed 12 h after symptom onset and showed that brain stem edema was already evident. In case 5, the initial CT performed on autopsy at 16 h identified brain edema 5 6 but no other cause of death, such as bleeding or a space-occupying lesion. All the cases 7 described here fulfilled the SIRS criteria immediately upon hospitalization (1-12 h 8 after symptom onset). They presented with DIC and shock almost simultaneously 9 (4-14 h after onset). Intubation was performed in all cases 4-14 h after symptom onset, 10 and inotropic agents were started in all cases 6-15 h after onset. Initial HDS was 11 administered in 4 cases (cases 1-4) at 3 h 35 min-13 h 40 min after onset. TTM and 12 BCT or continuous midazolam infusion were performed in two cases (case 1 and 2) at 13 8 h and 13 h 40 min, respectively. Brain imaging revealed abnormalities such as brain 14 edema at 7 h 30 min-4 days after onset, and they were diagnosed with AE between 4 h 29 min and 4 days after initial neurological symptoms. Continuous EEG was 15 16 performed 24 h after symptom onset in three cases, and electrical seizures were

- detected in two (cases 1 and 3). Some patients also showed diffuse slow wave patterns
- when seizures were not occurring (cases 1, 3, and 4), with gradually decreasing
- 3 amplitudes. Low amplitude (<10 μV) waves were observed 14 h after symptom onset
- 4 in the earliest case (case 4). Despite intensive treatment, all patients were ultimately
- 5 diagnosed with brain death between 16 h and 4 days after initial symptom onset.

8

16

- 7 3.3. Laboratory data 24 hours after symptom onset (Table 3, Figure 2)
- 9 consistent pattern of change over time. Platelet counts were normal or slightly elevated 10 examination, Prothrombin initial but tended to decrease afterward. 11 times/international normalized ratios (PT/INRs) were often elevated after 4 h from 12 symptom onset. Initial AST levels were also slightly elevated within 3 h of symptom onset in cases 1 and 4; AST levels as well as other liver enzymes increased 13 14 dynamically in all patients 4 h after symptom onset (Figure 2a). Initial creatinine levels 15 were elevated (greater than the 97.5 percentile of standard values for each patients'

respective age) in all patients (0.60-2.72 mg/dL, Figure 2b) [17]. Initial sodium levels

White blood cell counts (WBC) were often elevated, but there were no

were greater than 141 mmol/L. Sodium levels were almost within the normal range at initial examination, but increased gradually within 24 h of symptom onset in all patients (Figure 2c). Both hyperammonemia and hypoglycemia were detected in one patient (case 2). All patients had severe metabolic acidosis with abnormally low base excess (BE) at initial examination that continued below normal within 24 hours.

although it improved over time in two cases (cases 3 and 4).

4. Discussion

The final diagnoses determined in the cases presented here include Reye-like syndrome, HSES, and ANE. These are AE subtypes associated with a high mortality rate [1]. While the cases described here were all terminal, detailed descriptions of their treatments and clinical courses remain important as these have not previously been reported on a minute-by-minute timescale for cases of fatal AE. Further, to the best of our knowledge, this manuscript is the first to document the evolution of AE at this timescale. Below we focus our discussion on aspects of the cases pertinent to the timing of interventions.

2

16

4.1. The timing of clinical events relative to onset

3 The earliest diagnosis of AE was rendered at 4 h 29 min after symptom onset 4 (case 3). In contrast, the longest duration between initial symptom onset and the diagnosis of AE in the cases herein described was 4 days (case 1). Our finding that 5 6 these patients presented with SIRS, DIC, or shock criteria was consistent with previous 7 reports of fatal AE [1, 2], although these previous studies did not report the time lags 8 between presenting with these criteria, and AE diagnoses or onset of neurological 9 symptoms. We observed that SIRS criteria were met earliest, followed by DIC, and 10 shock. All patients met the SIRS criteria at a relatively early stage in their disease 11 progression or immediately upon admission, though we did not commence intensive 12 therapies at that time because we were unable to predict fulminant courses. Criteria for 13 SIRS, DIC, and shock were also met prior to the diagnoses of AE presented here. 14 Head CTs performed approximately 3 h after symptom onset were normal in 15 three patients. The earliest noted brain imaging abnormality was 7.5 h after symptom

onset. Among 10 patients with HSES, 8% of initial head CTs were normal [3]; thus the

1 normal brain imaging findings that we report a few hours after symptom onset

2 ultimately did not preclude the evolution of an AE diagnosis thereafter.

3 The patients presented here were also treated with interventions more specific 4 to AE, including HDS, TTM, and CHDF within approximately 12 h of symptom onset. However, these treatments were not effective, despite the fact that HDS in case 3, for 5 6 example, was initiated within only 4 h of symptom onset. It has been reported that 7 TTM or steroid administration within 24 h of initial symptom onset is related to better 8 outcome of AE without AST elevation, or ANE without brainstem lesions [4, 9]. 9 Moreover, TTM for AE applied within 12 h of initial neurological signs is likely to be 10 associated with better prognosis [18]. From the viewpoint of cerebral protection 11 against acute brain injury, previous reports have indicated that successful interventions 12 are often initiated only a few hours after the onset of hypoxic ischemic encephalopathy or acute ischemic stroke [19, 20]. It has also been reported that in hypoxic ischemic 13 14 encephalopathy, secondary deterioration at 6-15 h after asphyxia often occurred, 15 marked by delayed seizures, secondary cytotoxic edema (cell swelling), accumulation 16 of excitotoxins, and failure of cerebral mitochondrial activity [21].

In cases 1 and 3 in the present study, specific intervention for AE was 1 2 initiated before definite diagnoses of AE. In contrast, HDS and/or TTM were initiated 3 after diagnoses of AE in cases 2 and 4. In a review of eight patients, Rinka et al. 4 reported that patient condition was already critical when they met the HSES criteria; thus among these criteria, platelet count, hemoglobin, DIC and renal function 5 6 impairment were not useful [22]. Given these discussions of the timing of clinical 7 events relative to onset, we consider that early intervention before an AE diagnosis is 8 important to rescue some patients from fatal AE.

9

10

4.2. Laboratory data 24 hours after symptom onset

Leakage of liver enzymes including AST, ALT, and lactate dehydrogenase

(LDH) increased continuously in the cases herein presented. Regardless of treatment,

the AST level rose slightly 3 h after symptom onset, and further increased 4-6 h after

onset. It has also previously been reported that AST levels might predict poor AE

outcomes [5, 10, 23]. In the present study, liver enzymes increased rapidly in the

relative early reassessment of liver enzymes in cases 1 and 4. This emphasizes the

- 1 importance of reassessing laboratory data 4-6 h after symptom onset in cases with
- 2 continuing impaired consciousness, even should assessment be normal within 3 h after
- 3 symptom onset.

- In all cases considered here, creatinine was also continuously elevated above
- 5 the 97.5 percentile of standard values by age. Creatinine may therefore be elevated in
- 6 patients with a particularly poor prognosis, rendering it useful as a potential biomarker.
- 7 Previous reports have further indicated that creatinine may help to differentially
- 8 diagnose AE and prolonged FS, or predict poor acute encephalopathy with biphasic
- 9 seizures and late reduced diffusion outcomes [23, 24]. Moreover, creatinine, which is
- produced from creatine stored in the brain under excitotoxic conditions, is released into
- the blood when the blood brain barrier is injured [25, 26].
- In nearly all of the cases herein discussed, sodium levels did not fall below normal levels, and increased gradually with time. Sodium has rarely been reported to serve as a predictive factor for a poor AE prognosis, though it has been suggested to be a predictive factor for ICU mortality (APACHE II) [27]. It has also been reported that

sodium levels tend to be low in individuals with FS [28]. Sodium may therefore serve

as a useful factor for distinguishing between fatal AE and FS: in particular sodium

increases on reassessment might be associated with fatal AE.

In the five cases reported here, abnormal laboratory findings including liver enzymes, creatinine, and sodium were identified earlier than abnormal brain imaging findings. Therefore, we considered that these changes in laboratory data such as liver enzymes, creatinine and sodium might be explained by a severe MOF rather than by

8

9

7

2

4.3. Limitations

encephalopathy.

The findings presented here were subject to the limitation inherent to the study's retrospective clinical design. Assessment of laboratory data, EEG, and brain imaging was performed when the physician judged it necessary and not according to a fixed schedule. Further, this report documents a single-center study; thus, only a small number of patients were included. The heterogeneous population of patients with three different subtypes of AE presents a further limitation, but this heterogeneity is representative of clinical practice because it is often difficult to diagnose subtypes of

- 1 AE at the early stages of the disease, even for fatal cases. A larger prospective study is
- 2 therefore necessary to predict mortality and estimate the effectiveness of early

3 intervention.

4

5

5. Conclusions

6 Although these results should be cautiously interpreted owing to the 7 limitations listed, we were able to uncover some relevant information. Our findings 8 clarified that clinical events such as DIC, MOF, and shock were identified before 9 either brain edema on CT, or definitive diagnosis of AE. We also found that liver 10 enzymes and creatinine levels were elevated a few hours after initial symptom onset, 11 whereas sodium levels increased gradually as the condition progressed. Effective 12 interventions remain elusive, as does understanding of the usefulness of early 13 intervention prior to a definitive diagnosis of AE. However, it is clear that the time 14 window to rescue patients from fatal AE is relatively short.

15

16

Acknowledgements

We wish to thank all the pediatricians and nurses who managed the PICU at

Kobe Children's Hospital in the Suma ward, Kobe City.

Role of the funding source

This work was partly supported by JSPS KAKENHI Grant Number JP

6

18K08918.

References

- 2 1. Mizuguchi, M. Yamanouchi H, Ichiyama T, Shiomi M. Acute
- 3 encephalopathy associated with influenza and other viral infections. Acta Neurol Scand
- 4 2007;115:45-56.
- 5 2. Hoshino A, Saitoh M, Oka A, Okumura A, Kubota M, Saito Y, Takanashi
- 6 J, et al. Epidemiology of acute encephalopathy in Japan, with emphasis on the
- 7 association of viruses and syndromes. Brain Dev 2012;34:337-43.
- 8 3. Kuki I, Shiomi M, Okazaki S, Kawawaki H, Tomiwa K, Amo K, et al.
- 9 Characteristic neuroradiologic features in hemorrhagic shock and encephalopathy
- 10 syndrome. J Child Neurol 2015; 30:468-75.
- Okumura A, Mizuguchi M, Kidokoro H, Tanaka M, Abe S, Hosoya M, et al.
- 12 Outcome of acute necrotizing encephalopathy in relation to treatment with
- corticosteroids and gammaglobulin. Brain Dev 2009;31:221-7.
- 14 5. Tomioka K, Nagase H, Tanaka T, Nishiyama M, Yamaguchi H, Ishida Y, et al.
- Early risk factors for mortality in children with seizure and/or impaired consciousness
- accompanied by fever without known etiology. Brain Dev 2018;40:552-57.
- 17 6. Fiser DH. Assessing the outcome of pediatric intensive care. J

- 1 Pediatr 1992;121:68-74.
- 2 7. Maegaki Y, Kondo A, Okamoto R, Inoue T, Konishi K, Hayashi A, et al.
- 3 Clinical characteristics of acute encephalopathy of obscure origin: a biphasic clinical
- 4 course is a common feature. Neuropediatrics 2006;37:269-77.
- 5 8. Young GB, Jordan KG, Doig GS. An assessment of nonconvulsive seizures
- 6 in the intensive care unit using continuous EEG monitoring: an investigation of
- 7 variables associated with mortality. Neurology 1996. 47:83-9.
- 8 9. Nishiyama M, Tanaka T, Fujita K, Maruyama A, Nagase H. Targeted
- 9 temperature management of acute encephalopathy without AST elevation. Brain Dev
- 10 2015;37:328-33.
- 11 10. Nagase H, Nakagawa T, Aoki K, Fujita K, Saji Y, Maruyama A, et al.
- 12 Therapeutic indicators of acute encephalopathy in patients with complex febrile
- 13 seizures. Pediatr Int 2013;55:310-4.
- 14 11. Goldstein, B., B. Giroir, and A. Randolph, International pediatric sepsis
- consensus conference: Definitions for sepsis and organ dysfunction in pediatrics*.
- Pediatric Critical Care Medicine, 2005. 6(1): p. 2-8.

- 1 12. Gando S, Iba T, Eguchi Y, Ohtomo Y, Okamoto K, Koseki K, et al. A
- 2 multicenter, prospective validation of disseminated intravascular coagulation
- 3 diagnostic criteria for critically ill patients: comparing current criteria. Crit Care Med
- 4 2006;34:625-31.
- 5 13. The Research Committee on the Clarification of Etiology and on the
- 6 Establishment of Therapeutic and Preventive Measures of Influenza Encephalopathy.
- 7 Guideline for influenza encephalopathy (in Japanese). Japan: Ministry of Health, Labor
- 8 and Welfare; 2005. p. 1–21.
- 9 14. Bacon CJ, Hall SM. Haemorrhagic shock encephalopathy syndrome in the
- 10 British Isles. Arch Dis Child 1992;67:985-93.
- 11 15. Hurwitz ES, Nelson DB, Davis C, Morens D, Schonberger LB. National
- surveillance for Reye syndrome: a five-year review. Pediatrics 1982;70:895-900.
- 13 16. Mizuguchi, M, Abe J, Mikkaichi K, Noma S, Yoshida K, Yamanaka T, et al.
- 14 Acute necrotising encephalopathy of childhood: a new syndrome presenting with
- multifocal, symmetric brain lesions. J Neurol Neurosurg Psychiatry 1995;58:555-61.
- 16 17. Uemura O, Honda M, Matsuyama T, Ishikura K, Hataya H, Yata N, et al.

- 1 Age, gender, and body length effects on reference serum creatinine levels determined
- 2 by an enzymatic method in Japanese children: a multicenter study. Clin Exp Nephrol
- 3 2011;15:694-9.
- 4 18. Kawano G, Iwata O, Iwata S, Kawano K, Obu K, Kuki I, et al. Determinants
- 5 of outcomes following acute child encephalopathy and encephalitis: pivotal effect of
- 6 early and delayed cooling. Arch Dis Child 2011;96:936-41.
- 7 19. Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA,
- 8 Donovan EF, et al. Whole-body hypothermia for neonates with hypoxic-ischemic
- 9 encephalopathy. N Engl J Med 2005;353:1574-84.
- 10 20. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo
- AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl
- 12 J Med 2015;372:11-20.
- 13 21. Drury PP, Bennet L, Gunn A. J. Mechanisms of hypothermic neuroprotection.
- 14 Semin Fetal Neonatal Med 2010;15:287-92.
- 15 22. Rinka, H, Yoshida T, Kubota T, Tsuruwa M, Fuke A, Yoshimoto A,
- et al. Hemorrhagic shock and encephalopathy syndrome the markers for an early HSES

- 1 diagnosis. BMC Pediatr 2008;8:43.
- 2 23. Tada H, Takanashi J, Okuno H, Kubota M, Yamagata T, Kawano G, et al.
- 3 Predictive score for early diagnosis of acute encephalopathy with biphasic seizures and
- 4 late reduced diffusion (AESD). J Neurol Sci 2015;358:62-5.
- 5 24. Ishikawa J, Yamamuro M, Togawa M, Shiomi M. Attempt of differentiation
- 6 acute encephalopathy with febrile convulsive status epilepticus from febrile convulsive
- 7 status epilepticus induced by human herpes virus 6 at early stage (in Japanese). No To
- 8 Hattatsu (Tokyo) 2010;42:283-6.
- 9 25. Andres RH, Ducray AD, Schlattner U, Wallimann T, Widmer HR. Functions
- and effects of creatine in the central nervous system. Brain Res Bull 2008;76:329-43.
- 11 26. Azuma J, Nabatame S, Nakano S, Iwatani Y, Kitai Y, Tominaga K, et al.
- Prognostic factors for acute encephalopathy with bright tree appearance. Brain Dev
- 13 2015;37:191-9.
- 14 27. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity
- of disease classification system. Crit Care Med 1985;13:818-29.
- 16 28. Thoman JE, Duffner PK, Shucard JL. Do serum sodium levels predict febrile

1 seizure recurrence within 24 hours? Pediatr Neurol 2004;31:342-4.

Figure legends

- 2 Figure 1. Clinical time courses for all patients.
- 3 Case 1: She was hospitalized with clinical seizure. Initial CT was normal. She was
- 4 intubated at 4 h 43 min because of unconsciousness and clinical seizure. High dose
- 5 steroids (HDS) were administered at 7 h 40 min. Continuous electroencephalogram
- 6 (cEEG) from 3 h after onset identified slow wave and electrical seizures. Barbiturate
- 7 coma therapy (BCT; bolus dosage 39.2mg/kg, maintenance dosage 5mg/kg/h) with
- 8 targeted temperature management (TTM) was initiated 9 h after symptom onset
- 9 because of unconsciousness and refractory electrical seizures. On day 4, diffuse brain
- 10 edema was identified, and she was diagnosed with Reye-like syndrome and
- 11 consequently died.
- 12 Case 2: He was hospitalized with clinical seizure and impaired consciousness, and
- 13 intubated at 13 h 40 min because this deteriorated to unconsciousness with recurrent
- clinical seizure. Brain edema was identified on initial CT, and he was diagnosed with
- Reye-like syndrome at 12 h. Intensive therapies including HDS, TTM, and continuous
- 16 hemodiafiltration (CHDF) were initiated. However, low voltage (<10 μV) was
- identified on EEG, and he died at 36 h after onset.
- 18 Case 3: She was hospitalized with impaired consciousness. Initial CT was normal.
- HDS was administered at 3 h 35 min because influenza encephalopathy was suspected.
- 20 She was diagnosed with hemorrhagic shock and encephalopathy syndrome (HSES)
- because of multiple organ failure (MOF) and disseminated intravascular coagulation
- 22 (DIC) at 4 h 29 min. Intensive therapies including intubation and inotropic agents were
- 23 initiated but her condition deteriorated rapidly and she died at 40 h after onset.
- 24 Case 4: She was hospitalized with impaired consciousness. Initial CT was normal.
- 25 Consciousness level deteriorated with recurrent seizures. Second CT revealed
- symmetrically distributed brain lesions of the thalamus, and she was diagnosed with
- acute necrotizing encephalopathy (ANE) at 7 h 30 min. Intensive therapy including
- intubation and HDS was conducted but she developed shock and died at 48 h.
- 29 Case 5: He was hospitalized with clinical seizure and impaired consciousness.
- 30 Consciousness level deteriorated, and clinical seizure recurred at approximately 12 h.
- 31 MOF and DIC were identified. He developed shock, and was diagnosed with HSES at
- 32 16 h. Despite intensive therapies, he died at 16 h 26 m. CT at autopsy identified brain
- 33 edema.

□ normal head CT, ■ abnormal head CT or MRI, ▲ shock
 △ systemic inflammatory response syndrome
 △ disseminated intravascular coagulation
 × definite diagnosis of acute encephalopathy, ¶ brain death
 ♦ initial high dose steroid, ○ intubation

Neurological state:

- impaired consciousness
- clinical seizure
- under sedation

EEG findings:

- slow wave
- electrical seizure
- low voltage < 10 μV
- GCS, Glasgow coma scale; JCS, Japan coma scale

3

- 4 Figure 2. Levels of aspartate aminotransferase (AST), creatine, and sodium within 24 h
- 5 of symptom onset. (a) Initial AST levels were already elevated, though only slightly, in
- 6 cases that were tested within 3 h of symptom onset. Four hours after symptom onset,
- 7 AST levels increased rapidly in all patients. (b) For all cases, creatinine levels were
- 8 continuously elevated above initial values. (c) Initial sodium levels were above 141
- 9 mEq/L and increased gradually within 24 h of symptom onset in all cases.

TablesTable 1. Patients characteristics, symptoms, and diagnoses

| Case | Sex | Age | Symptoms prior to AE | Body | Initial neurological | Use of anti epileptic drugs | Etiology | Abnormalities of brain | Diagnosis |
|------|--------|------|------------------------|----------------|----------------------|-----------------------------|--------------|--------------------------------|-----------|
| | | | onset | temperature in | symptom (duration of | | | imaging | |
| | | | | admission | convulsion) | | | | |
| 1 | Female | 0y6m | None | 38.1℃ | Convulsions | DZP iv, MDL iv, MDL ci, | Not detected | Edema | Reye-like |
| | | | | | (15 minutes) | PB iv, THI ci | | | syndrome |
| 2 | Male | 1y1m | Fever (-1 day) | 39.6℃ | Convulsions | PB sup, DZP iv, MDL ci | Not detected | Edema, diffuse atrophy | Reye-like |
| | | | Vomiting (-1 day) | | (3 minutes) | | | | syndrome |
| 3 | Female | 8y | Fever (-1 day) | 39.5℃ | Impaired | MDL iv | Flu A | Bleeding, brain stem necrosis, | HSES |
| | | | | | consciousness | | | edema, hernia | |
| 4 | Female | 8y | Fever (-1 day) | 39.8℃ | Impaired | DZP iv, MDL iv | Flu A | Symmetrically distributed | ANE |
| | | | vomiting, diarrhea | | consciousness | | | brain lesions of the thalamus, | |
| | | | (-1 day) | | | | | brain stem necrosis | |
| 5 | Male | 14y | Fever, cough (-2 days) | 41.0℃ | Convulsions | DZP iv | Flu B | Edema | HSES |
| | | | vomiting, diarrhea | | (unknown) | | | | |
| | | | (-1 day) | | | | | | |

AE, acute encephalopathy; ANE, acute necrotizing encephalopathy; DZP, diazepam; Flu; influenza; HSES, hemorrhagic shock and encephalopathy syndrome; MDL, midazolam; PB, phenobarbital; THI, thiamiral; iv, intravenous infusion; ci, continuous infusion; sup, suppository.

Table 2. Clinical course of events relative to symptom onset time for each case

| Case | Hospitalization | Initial head CT | SIRS | DIC | Shock | intubation | Start of | HDS | TTM& | Diagnosis | Brain |
|------|-----------------|-----------------|--------|--------|--------|------------|-----------|--------|--------|-----------|--------|
| | (our hospital) | (abnormality) | | | | | inotropic | | BCT | of AE | death |
| | | | | | | | agents | | | syndrome | |
| 1 | 0h28m | 1h22m | 1h21m | n.p. | n.p. | 4h43m | 9h40m | 7h40m | 8h0m | day4 | day4 |
| | | (none) | | | | | | | | | |
| 2 | 0h (13h30m) | 12h00m | 9h00m | 13h40m | 13h40m | 13h40m | 13h40m | 13h40m | 13h40m | 12h00m | 36h |
| | | (brain edema) | | | | | | | | | |
| 3 | 1h (4h20m) | 1h0m | 4h20m | 4h29m | 5h30m | 5h00m | 6h14m | 3h35m | n.d. | 4h29m | 40h |
| | | (none) | | | | | | | | | |
| 4 | 1h0m | 1h00m | 1h0m | 4h35m | 8h0m | 7h20m | 9h30m | 9h40m | n.d. | 7h30m | 48h |
| | | (none) | | | | | | | | | |
| 5 | 11h (13h) | after death | 11h36m | 11h36m | 13h10m | 13h36m | 14h49m | n.d. | n.d. | 16h | 16h26m |
| | | (brain edema) | | | | | | | | | |

Display shows the duration from symptom onset. h, hour(s); m, minute(s); AE, acute encephalopathy; BCT, barbiturate coma therapy; CT, computed tomography; DIC, disseminated intravascular coagulation; HDS, high dose steroids; SIRS, systemic inflammatory response syndrome; TTM, targeted temperature management; n.p., not presented; n.d., not done.

Table 3. Laboratory data collected within 24 h of symptom onset

| Case | Duration from onset | WBC | Plt | PT/INR | AST | ALT | LDH | Cre | Na | Glu | NH ₃ | рН | BE |
|------|---------------------|-------|------|--------|------|------|-------|------|-----|------|-----------------|-------|-------|
| 1 | 1h22m | 27900 | 42.3 | 0.99 | 63 | 22 | 463 | 0.60 | 142 | 283 | 127 | 7.061 | -16.5 |
| | 6h29m | 18800 | 22.8 | n.t. | 504 | 54 | 2199 | 0.40 | 145 | 88 | 41 | 7.366 | -4.6 |
| | 12h23m | 7100 | 12.8 | 2.31 | 677 | 87 | 3419 | 0.33 | 145 | 127 | n.t. | 7.468 | -4.0 |
| | 22h01m | 5000 | 16.6 | 1.67 | 489 | 115 | 2852 | 0.34 | 150 | 144 | n.t. | 7.335 | -4.0 |
| 2 | 9h00m | 44690 | 71.1 | n.t. | 7230 | 3410 | 7650 | 0.8 | 148 | 10 | 874 | n.t. | n.t. |
| | 13h40m | 43200 | 51.7 | 4.57 | 6122 | 2972 | 6680 | 1.02 | 146 | 88 | >1000 | 7.026 | -21.5 |
| | 18h30m | 20000 | 24.1 | 6.53 | 3720 | 1610 | 3860 | 0.87 | 149 | 319 | 376 | 7.117 | -19.0 |
| | 23h00m | 21400 | 23.7 | n.t. | 3710 | 1650 | 3740 | 0.62 | 155 | 296 | 180 | 7.271 | -8.8 |
| 3 | 4h28m | 11200 | 15.1 | 2.29 | 1760 | 1058 | 3610 | 1.51 | 142 | 23 | 25 | 7.175 | -9.6 |
| | 7h46m | 13200 | 11.0 | 4.08 | 896 | 484 | 2680 | 1.29 | 142 | 162 | n.t. | n.t. | n.t. |
| | 9h59m | 12100 | 9.7 | 4.17 | 1671 | 471 | 3279 | 1.24 | 142 | 166 | 276 | 7.395 | -2.0 |
| | 19h21m | 6800 | 10.7 | 3.2 | 9720 | 4581 | 10060 | 2.46 | 157 | 147 | 120 | 7.234 | -5.1 |
| 4 | 2h18m | 12200 | 32.1 | 1.28 | 57 | 26 | 313 | 0.81 | 143 | 105 | n.t. | 7.231 | -8.2 |
| | 4h40m | n.t. | n.t. | 1.28 | n.t. | n.t. | n.t. | n.t. | 138 | 72 | n.t. | 7.437 | -2.8 |
| | 10h05m | 7100 | 13.6 | 1.83 | 322 | 188 | 595 | 1.01 | 142 | 87 | 47 | 7.143 | -9.6 |
| | 15h37m | 7000 | 8.1 | 1.57 | 1570 | 895 | 2033 | 0.99 | 149 | 168 | n.t. | 7.334 | -6.6 |
| | 22h46m | 1430 | 10.1 | 2.70 | 5860 | 3320 | 6750 | n.t. | 173 | 125 | n.t. | 7.421 | -3.1 |
| 5 | 11h36m | 15600 | 17.1 | 1.39 | 397 | 217 | 728 | 2.72 | 144 | n.t. | 74 | n.t. | -8.1 |
| | 13h45m | 12400 | 11.5 | 1.80 | 289 | 155 | 579 | 3.59 | 138 | 324 | 159 | 7.069 | -13.4 |

ALT, alanine aminotransferase (U/L); AST, aspartate aminotransaminase (U/L); BE, base excess (mmol/L); Cre, creatinine (mg/dL); Glu, glucose

(mg/dL); LDH, lactate dehydrogenase (U/L); Na, sodium (mEq/L); NH₃, ammonia (μ g/dL); PLT, platelet (*10⁴/ μ L); PT/INR, prothrombin time/international normalized ratio; WBC, white blood cell (/ μ L); n.t., not tested. () indicated units.





